Cardiac Troponins and SARS-CoV-2: Subclinical Myocardial Injury as he Long Shadow of the Pandemic

Key Points

• To investigate the association between SARS-CoV-2 infection and subclinical myocardial injury as indicated by cardiac troponin levels.
• Evaluated patients post-SARS-CoV-2 infection for myocardial injury using cardiac troponin biomarkers.
• Analyzed cardiac health through non-invasive imaging and clinical assessments.
• Compared troponin levels with control groups to assess the impact of viral infection.
• Patients with SARS-CoV-2 showed elevated cardiac troponin levels (mean troponin level 0.03 ng/mL, p<0.01) compared to controls.
• Subclinical myocardial injury was observed in 30% of SARS-CoV-2 patients, indicating potential long-term cardiovascular effects.
• Follow-up revealed persistent troponin elevation correlating with adverse cardiac events (HR 2.5, 95% CI 1.5-4.1, p<0.001).